IDEAS home Printed from https://ideas.repec.org/a/bpj/fhecpo/v27y2024i1p29-116n1002.html
   My bibliography  Save this article

Valuing the Societal Impact of Medicines and Other Health Technologies: A User Guide to Current Best Practices

Author

Listed:
  • Shafrin Jason

    (Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA, USA)

  • Kim Jaehong

    (Center for Healthcare Economics and Policy, FTI Consulting, Los Angeles, CA, USA)

  • Cohen Joshua T.

    (Center for the Evaluation of Value and Risk in Health, Tufts Medical Center, Boston, MA, USA)

  • Garrison Louis P.

    (The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, University of Washington, Seattle, WA, USA)

  • Goldman Dana A.

    (Schaeffer Center for Health Policy & Economics, University of Southern California, Los Angeles, CA, USA)

  • Doshi Jalpa A.

    (Division of General Internal Medicine, University of Pennsylvania, Philadelphia, PA, USA)

  • Krieger Joshua

    (Harvard Business School, Harvard University, Boston, MA, USA)

  • Lakdawalla Darius N.

    (Schaeffer Center for Health Policy & Economics, University of Southern California, Los Angeles, CA, USA)

  • Neumann Peter J.

    (Center for the Evaluation of Value and Risk in Health, Tufts Medical Center, Boston, MA, USA)

  • Phelps Charles E.

    (Economics, Public Health Sciences, University of Rochester, Rochester, NY, USA)

  • Whittington Melanie D.

    (Center for the Evaluation of Value and Risk in Health, Tufts Medical Center, Boston, MA, USA)

  • Willke Richard

    (Scintegral Health Economics, Lawrenceville, NJ, USA)

Abstract

This study argues that value assessment conducted from a societal perspective should rely on the Generalized Cost-Effectiveness Analysis (GCEA) framework proposed herein. Recently developed value assessment inventories – such as the Second Panel on Cost-Effectiveness’s “impact inventory” and International Society of Pharmacoeconomics Outcomes Research (ISPOR) “value flower” – aimed to more comprehensively capture the benefits and costs of new health technologies from a societal perspective. Nevertheless, application of broader value elements in practice has been limited in part because quantifying these elements can be complex, but also because there have been numerous methodological advances since these value inventories have been released (e.g. generalized and risk-adjusted cost effectiveness). To facilitate estimation of treatment value from a societal perspective, this paper provides an updated value inventory – called the GCEA value flower – and a user guide for implementing GCEA for health economics researchers and practitioners. GCEA considers 15 broader value elements across four categories: (i) uncertainty, (ii) dynamics, (iii) beneficiary, and (iv) additional value components. The uncertainty category incorporates patient risk preferences into value assessment. The dynamics category petals account for the evolution of real-world treatment value (e.g. option value) and includes drug pricing trends (e.g. future genericization). The beneficiary category accounts for the fact health technologies can benefit others (e.g. caregivers) and also that society may care to whom health benefits accrue (e.g. equity). Finally, GCEA incorporates additional broader sources of value (e.g. community spillovers, productivity losses). This GCEA user guide aims to facilitate both the estimation of each of these value elements and the incorporation of these values into health technology assessment when conducted from a societal perspective.

Suggested Citation

  • Shafrin Jason & Kim Jaehong & Cohen Joshua T. & Garrison Louis P. & Goldman Dana A. & Doshi Jalpa A. & Krieger Joshua & Lakdawalla Darius N. & Neumann Peter J. & Phelps Charles E. & Whittington Melani, 2024. "Valuing the Societal Impact of Medicines and Other Health Technologies: A User Guide to Current Best Practices," Forum for Health Economics & Policy, De Gruyter, vol. 27(1), pages 29-116.
  • Handle: RePEc:bpj:fhecpo:v:27:y:2024:i:1:p:29-116:n:1002
    DOI: 10.1515/fhep-2024-0014
    as

    Download full text from publisher

    File URL: https://doi.org/10.1515/fhep-2024-0014
    Download Restriction: For access to full text, subscription to the journal or payment for the individual article is required.

    File URL: https://libkey.io/10.1515/fhep-2024-0014?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Bhattacharya, Jayanta & Vogt, William B, 2003. "A Simple Model of Pharmaceutical Price Dynamics," Journal of Law and Economics, University of Chicago Press, vol. 46(2), pages 599-626, October.
    2. Jonathan D. Campbell & Melanie D. Whittington & Steven D. Pearson, 2023. "An Alternative Measure of Health for Value Assessment: The Equal Value Life-Year," PharmacoEconomics, Springer, vol. 41(10), pages 1175-1182, October.
    3. Bobinac, Ana & van Exel, N. Job A. & Rutten, Frans F.H. & Brouwer, Werner B.F., 2010. "Caring for and caring about: Disentangling the caregiver effect and the family effect," Journal of Health Economics, Elsevier, vol. 29(4), pages 549-556, July.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Dhaval M. Dave, 2013. "Effects of Pharmaceutical Promotion: A Review and Assessment," NBER Working Papers 18830, National Bureau of Economic Research, Inc.
    2. McDonald, Rebecca & Powdthavee, Nattavudh, 2018. "The Shadow Prices of Voluntary Caregiving: Using Panel Data of Well-Being to Estimate the Cost of Informal Care," IZA Discussion Papers 11545, Institute of Labor Economics (IZA).
    3. Gregory J. King & Xiuli Chao & Izak Duenyas, 2019. "Who Benefits When Prescription Drug Manufacturers Offer Copay Coupons?," Management Science, INFORMS, vol. 65(8), pages 3758-3775, August.
    4. Eve Wittenberg & Adrianna Saada & Lisa Prosser, 2013. "How Illness Affects Family Members: A Qualitative Interview Survey," The Patient: Patient-Centered Outcomes Research, Springer;International Academy of Health Preference Research, vol. 6(4), pages 257-268, December.
    5. Vincenzo Atella & Jay Bhattacharya & Lorenzo Carbonari, 2008. "Pharmaceutical Industry, Drug Quality and Regulation: Evidence from US and Italy," NBER Working Papers 14567, National Bureau of Economic Research, Inc.
    6. Darius Lakdawalla & Tomas Philipson & Y. Richard Wang, 2006. "Intellectual Property and Marketing," NBER Working Papers 12577, National Bureau of Economic Research, Inc.
    7. Panattoni, Laura E., 2011. "The effect of Paragraph IV decisions and generic entry before patent expiration on brand pharmaceutical firms," Journal of Health Economics, Elsevier, vol. 30(1), pages 126-145, January.
    8. Patricia M. Danzon & Eric L. Keuffel, 2014. "Regulation of the Pharmaceutical-Biotechnology Industry," NBER Chapters, in: Economic Regulation and Its Reform: What Have We Learned?, pages 407-484, National Bureau of Economic Research, Inc.
    9. Rellstab, Sara & Bakx, Pieter & García-Gómez, Pilar & van Doorslaer, Eddy, 2020. "The kids are alright - labour market effects of unexpected parental hospitalisations in the Netherlands," Journal of Health Economics, Elsevier, vol. 69(C).
    10. Marie Blaise & Laetitia Dillenseger, 2023. "Informal Caregivers and Life Satisfaction: Empirical Evidence from the Netherlands," Journal of Happiness Studies, Springer, vol. 24(6), pages 1883-1930, August.
    11. Yoko Niimi, 2016. "The “Costs” of informal care: an analysis of the impact of elderly care on caregivers’ subjective well-being in Japan," Review of Economics of the Household, Springer, vol. 14(4), pages 779-810, December.
    12. Christopher P. Adams, 2021. "CBO's Simulation Model of New Drug Development: Working Paper 2021-09," Working Papers 57010, Congressional Budget Office.
    13. Norén, Anna, 2020. "Sick of my parents? Consequences of parental ill health on adult children," Working Paper Series 2020:1, IFAU - Institute for Evaluation of Labour Market and Education Policy.
    14. Young Kyung Do & Edward C. Norton & Sally C. Stearns & Courtney Harold Van Houtven, 2015. "Informal Care and Caregiver's Health," Health Economics, John Wiley & Sons, Ltd., vol. 24(2), pages 224-237, February.
    15. Alice M. Ellyson & Anirban Basu, 2018. "The New Prescription Drug Paradox: Pipeline Pressure and Rising Prices," NBER Working Papers 24387, National Bureau of Economic Research, Inc.
    16. Böckerman, Petri & Kortelainen, Mika & Salokangas, Henri & Vaalavuo, Maria, 2023. "Family Affair? Long-Term Economic and Mental Effects of Spousal Cancer," IZA Discussion Papers 16005, Institute of Labor Economics (IZA).
    17. Phantratanamongkol, Supanan & Casalin, Fabrizio & Pang, Gu & Sanderson, Joseph, 2018. "The price-volume relationship for new and remanufactured smartphones," International Journal of Production Economics, Elsevier, vol. 199(C), pages 78-94.
    18. Bom, Judith & Stöckel, Jannis, 2021. "Is the grass greener on the other side? The health impact of providing informal care in the UK and the Netherlands," Social Science & Medicine, Elsevier, vol. 269(C).
    19. Lisa Prosser & Scott Grosse & Eve Wittenberg, 2012. "Health Utility Elicitation," PharmacoEconomics, Springer, vol. 30(2), pages 83-86, February.
    20. S. Wouters & N. Exel & M. Donk & K. Rohde & W. Brouwer, 2015. "Do people desire to be healthier than other people? A short note on positional concerns for health," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 16(1), pages 47-54, January.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:bpj:fhecpo:v:27:y:2024:i:1:p:29-116:n:1002. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Peter Golla (email available below). General contact details of provider: https://www.degruyter.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.